Nuvation Bio/$NUVB
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Nuvation Bio
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
Ticker
$NUVB
Sector
Primary listing
NYSE
Industry
Pharmaceuticals
Headquarters
Employees
273
ISIN
US67080N1019
Website
Nuvation Bio Metrics
BasicAdvanced
$698M
-
-$2.03
1.37
-
Price and volume
Market cap
$698M
Beta
1.37
52-week high
$3.97
52-week low
$1.54
Average daily volume
7.8M
Financial strength
Current ratio
9.012
Quick ratio
8.852
Long term debt to equity
0.915
Total debt to equity
2.721
Interest coverage (TTM)
-522.44%
Profitability
EBITDA (TTM)
-205.427
Gross margin (TTM)
16.29%
Net profit margin (TTM)
-5,534.21%
Operating margin (TTM)
-1,883.38%
Revenue per employee (TTM)
$40,000
Management effectiveness
Return on assets (TTM)
-23.33%
Return on equity (TTM)
-119.66%
Valuation
Price to revenue (TTM)
55.88
Price to book
1.66
Price to tangible book (TTM)
1.68
Price to free cash flow (TTM)
-3.886
Free cash flow yield (TTM)
-25.73%
Free cash flow per share (TTM)
-52.75%
Growth
Earnings per share change (TTM)
540.90%
3-year earnings per share growth (CAGR)
68.96%
What the Analysts think about Nuvation Bio
Analyst ratings (Buy, Hold, Sell) for Nuvation Bio stock.
Bulls say / Bears say
Nuvation Bio's submission of a New Drug Application (NDA) to the FDA for taletrectinib in October 2024 positions the company for potential commercialization in the U.S. by mid-2025, which could significantly boost revenue if approved. (beyondspx.com)
The acquisition of AnHeart Therapeutics in April 2024 added new product candidates and revenue streams, contributing to a positive operating cash flow of $53 million in the quarter ended September 30, 2024. (beyondspx.com)
As of September 30, 2024, Nuvation Bio maintained a strong liquidity position with $549.1 million in cash, cash equivalents, and marketable securities, providing a solid financial foundation for ongoing R&D activities. (beyondspx.com)
Nuvation Bio reported a net loss of $53.2 million for the quarter ended March 31, 2025, indicating ongoing financial challenges. (stocktitan.net)
The company's total liabilities increased by 369.6% from 2023 to 2024, raising concerns about its financial health and debt management. (marketbeat.com)
Nuvation Bio's earnings per share (EPS) was -$2.23 as of September 30, 2024, reflecting significant losses per share and potential dilution concerns. (fintel.io)
Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2025.
Nuvation Bio Financial Performance
Revenues and expenses
Nuvation Bio Earnings Performance
Company profitability
Nuvation Bio News
AllArticlesVideos
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for IBTROZI™ (taletrectinib), Manufactured by Nuvation Bio Inc.
GlobeNewsWire·3 weeks ago
US FDA approves Nuvation Bio's lung cancer therapy
Reuters·3 weeks ago
U.S. Food and Drug Administration Approves Nuvation Bio's IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Nuvation Bio stock?
Nuvation Bio (NUVB) has a market cap of $698M as of July 04, 2025.
What is the P/E ratio for Nuvation Bio stock?
The price to earnings (P/E) ratio for Nuvation Bio (NUVB) stock is 0 as of July 04, 2025.
Does Nuvation Bio stock pay dividends?
No, Nuvation Bio (NUVB) stock does not pay dividends to its shareholders as of July 04, 2025.
When is the next Nuvation Bio dividend payment date?
Nuvation Bio (NUVB) stock does not pay dividends to its shareholders.
What is the beta indicator for Nuvation Bio?
Nuvation Bio (NUVB) has a beta rating of 1.37. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.